Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret? -- Ignore unavailable to you. Want to Upgrade?

To: Ellen who wrote (1348)	7/28/1999 2:53:00 PM
From: Jim Roof	Read Replies (1) \| Respond to of 1432

Here's the skinny on the salesforce numbers. At the annual shareholders' meeting a couple of weeks back BTIM stated that Abbott was training 150 salespeople to take Hextend into the existing albumin and crystalloid markets and that the training would take place over the weekend (1.5 weeks ago). The sales staff would begin making calls a few days after they were trained. Here are the known facts. Abbott has trained 150 salespeople in the details and selling points of Hextend. These 150 people are expressly directed into the albumin/crystalloid market where, according shorts, no market exists. Therein lies the defining moment for longs and shorts alike. Shorts have long claimed that Hextend is nothing more than an equivalent for Hespan and as such Hextend cannot do battle with either albumin or crystalloids. Longs have believed that the phase III trials were so full of enouraging data that, despite the shortcomings of the trials design (designed merely for equivalency to speed up delivery to the marketplace), Hextend is indeed as Abbott has billed it - "A next generation blood volume expander". That's the scoop. It's looking more and more like Abbott is thinking like the longs based upon their marketing strategy. Jim